Patents by Inventor Christopher R.H. HALE

Christopher R.H. HALE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF A COMPOUND
    Publication number: 20240059662
    Abstract: Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 22, 2024
    Inventors: Christopher R.H. Hale, Yingqing Ran, Anantha Sudhakar
  • SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE
    Publication number: 20240025915
    Abstract: Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 25, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Brian M. Fox, Christopher R.H. Hale
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Publication number: 20220411433
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 29, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Kinase Inhibitors and Uses Thereof
    Publication number: 20220041620
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11236100
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Kinase inhibitors and uses thereof
    Patent number: 11203600
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: December 21, 2021
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier De Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20210147435
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 20, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Kinase Inhibitors and Uses Thereof
    Publication number: 20200087319
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier De Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Preparation and biological evaluation of viridicatumtoxin analogs
    Patent number: 10065924
    Abstract: In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: September 4, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Kyriacos C Nicolaou, Christopher R. H. Hale, Christian Nilewski, Heraklidia Ioannidou, Abdellatif El Marrouni
  • PREPARATION AND BIOLOGICAL EVALUATION OF VIRIDICATUMTOXIN ANALOGS
    Publication number: 20170210699
    Abstract: In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
    Type: Application
    Filed: July 22, 2015
    Publication date: July 27, 2017
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Kyriacos C NICOLAOU, Christopher R.H. HALE, Christian NILEWSKI, Heraklidia IOANNIDOU, Abdellatif EL MARROUNI
  • SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS
    Publication number: 20160318862
    Abstract: In one aspect, the present invention provides novel derivatives of ?12-PGJ3 and modular synthetic pathways to obtaining ?12-PGJ3 and derivatives thereof. In some aspects, the present derivatives of ?12-PGJ3 are useful as chemotherapeutic agents. The present disclosure also describes compositions of these derivatives as well as methods of use of the derivatives thereof.
    Type: Application
    Filed: September 25, 2014
    Publication date: November 3, 2016
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Kyriacos C. NICOLAOU, Philipp HERETSCH, Christopher R.H. HALE, Abdellatif El Marrouni EL GHZAOUI, Kiran Kumar PULUKURI, Ruocheng YU, Charles GROVE